JHH6_LIVER
HCC · Hepatocellular Carcinoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- HCC
- cancer_type_detailed
- Hepatocellular Carcinoma
- subtype
- —
- cancer_type
- HCC
- ccle_sample_id
- JHH6_LIVER
- synthetic_from_ccle
- true
- display_name
- JHH-6
- ccle_lineage
- liver
- ccle_lineage_subtype
- hepatocellular_carcinoma
- oncotree_code
- HCC
- cancer_type_detailed
- Hepatocellular Carcinoma
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.474
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.422
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.376
- XENOBIOTIC_METABOLISM+0.351
- ANGIOGENESIS+0.300
- TGF_BETA_SIGNALING+0.293
- NOTCH_SIGNALING+0.292
- HYPOXIA+0.265
- MITOTIC_SPINDLE+0.257
- WNT_BETA_CATENIN_SIGNALING+0.255
Top 10 suppressed
- E2F_TARGETS-0.152
- MYC_TARGETS_V1-0.147
- G2M_CHECKPOINT-0.087
- OXIDATIVE_PHOSPHORYLATION-0.066
- ALLOGRAFT_REJECTION-0.045
- KRAS_SIGNALING_DN-0.035
- PROTEIN_SECRETION-0.034
- SPERMATOGENESIS-0.027
- ESTROGEN_RESPONSE_LATE-0.017
- UV_RESPONSE_UP-0.000
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12696728 | — | — | 0.810 |
| 2 | 73A8C537-1F73-49FE-84BC-E9CC82D2A63E | — | — | 0.808 |
| 3 | BS_196BBNEJ | EPN | Posterior Fossa EPN | 0.800 |
| 4 | MBCProject_0381_T2_RNA | — | A | 0.799 |
| 5 | MBCProject_3216_T1_RNA | — | A | 0.799 |
| 6 | TCGA-60-2707-01A-01R-0851-07 | — | cohortSQ1 | 0.797 |
| 7 | TCGA-95-7039-01A-11R-1949-07 | — | cohortA1 | 0.782 |
| 8 | s0122159 | — | — | 0.775 |
| 9 | MNG721 | — | — | 0.759 |
| 10 | b556b718-38cf-498d-94c7-4e240fe57d48 | — | — | 0.745 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.474 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.422 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.376 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.351 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.293 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.292 | Inavolisib | — uncovered |
| HYPOXIA | 0.265 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.257 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.255 | Inavolisib | — uncovered |
| APOPTOSIS | 0.239 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.218 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.188 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.183 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.178 | Idelalisib | — uncovered |
| COAGULATION | 0.178 | Binimetinib | — uncovered |
| ADIPOGENESIS | 0.152 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.144 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.136 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.133 | Idelalisib | — uncovered |